DK4168033T3 - Indgivelse af cebp-beta-antagonist og fremgangsmåder til anvendelse - Google Patents

Indgivelse af cebp-beta-antagonist og fremgangsmåder til anvendelse

Info

Publication number
DK4168033T3
DK4168033T3 DK21828902.3T DK21828902T DK4168033T3 DK 4168033 T3 DK4168033 T3 DK 4168033T3 DK 21828902 T DK21828902 T DK 21828902T DK 4168033 T3 DK4168033 T3 DK 4168033T3
Authority
DK
Denmark
Prior art keywords
cebp
methods
antagonist administration
beta antagonist
beta
Prior art date
Application number
DK21828902.3T
Other languages
Danish (da)
English (en)
Inventor
Barry Jay Kappel
Gene Merutka
Jimmy Andrew Rotolo
Robert E Michel
Alice Susannah Bexon
Original Assignee
Sapience Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics Inc filed Critical Sapience Therapeutics Inc
Application granted granted Critical
Publication of DK4168033T3 publication Critical patent/DK4168033T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK21828902.3T 2020-06-21 2021-06-21 Indgivelse af cebp-beta-antagonist og fremgangsmåder til anvendelse DK4168033T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063041991P 2020-06-21 2020-06-21
US202063041989P 2020-06-21 2020-06-21
US202063041988P 2020-06-21 2020-06-21
US202063041990P 2020-06-21 2020-06-21
US202063041986P 2020-06-21 2020-06-21
US202163172560P 2021-04-08 2021-04-08
PCT/US2021/038264 WO2021262604A2 (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Publications (1)

Publication Number Publication Date
DK4168033T3 true DK4168033T3 (da) 2026-05-11

Family

ID=79281738

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21828902.3T DK4168033T3 (da) 2020-06-21 2021-06-21 Indgivelse af cebp-beta-antagonist og fremgangsmåder til anvendelse

Country Status (17)

Country Link
US (1) US20230218717A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168033B1 (cg-RX-API-DMAC7.html)
JP (1) JP7880618B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027054A (cg-RX-API-DMAC7.html)
CN (1) CN115768458A (cg-RX-API-DMAC7.html)
AU (1) AU2021297172B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022025880A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180559A1 (cg-RX-API-DMAC7.html)
DK (1) DK4168033T3 (cg-RX-API-DMAC7.html)
ES (1) ES3066151T3 (cg-RX-API-DMAC7.html)
FI (1) FI4168033T3 (cg-RX-API-DMAC7.html)
IL (1) IL299104A (cg-RX-API-DMAC7.html)
MX (1) MX2022016478A (cg-RX-API-DMAC7.html)
NZ (1) NZ795026A (cg-RX-API-DMAC7.html)
PT (1) PT4168033T (cg-RX-API-DMAC7.html)
WO (1) WO2021262604A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202213167B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119997967A (zh) * 2022-10-07 2025-05-13 智慧疗法有限公司 C/EBP-β拮抗剂和免疫调节剂的使用
WO2024216238A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Use of beta-catenin antagonist and immunomodulator
EP4694911A2 (en) * 2023-04-13 2026-02-18 Sapience Therapeutics, Inc. Administration of a beta-catenin antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228642A (zh) * 2013-02-22 2016-01-06 纽约市哥伦比亚大学理事会 通过抑制转录因子atf5来抑制肿瘤细胞的组合物和方法
CA2983030A1 (en) * 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
WO2018152446A2 (en) 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-penetrating atf5 polypeptides and uses thereof
PT3737399T (pt) 2018-01-03 2023-09-04 Sapience Therapeutics Inc Variantes do péptido atf5 e as respetivas utilizações
WO2020033555A2 (en) * 2018-08-08 2020-02-13 The Trustees Of Columbia University In The City Of New York Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells

Also Published As

Publication number Publication date
ES3066151T3 (en) 2026-05-11
EP4168033A4 (en) 2024-06-19
AU2021297172A1 (en) 2023-01-19
KR20230027054A (ko) 2023-02-27
EP4168033B1 (en) 2026-02-25
FI4168033T3 (fi) 2026-04-07
US20230218717A1 (en) 2023-07-13
IL299104A (en) 2023-02-01
PT4168033T (pt) 2026-03-24
BR112022025880A2 (pt) 2023-01-10
JP7880618B2 (ja) 2026-06-26
AU2021297172B2 (en) 2025-01-30
MX2022016478A (es) 2023-02-01
ZA202213167B (en) 2026-03-25
CA3180559A1 (en) 2021-12-30
EP4168033A2 (en) 2023-04-26
NZ795026A (en) 2026-03-27
JP2023531683A (ja) 2023-07-25
WO2021262604A3 (en) 2022-02-17
WO2021262604A2 (en) 2021-12-30
CN115768458A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
DK3966207T3 (da) Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf
DK3966206T3 (da) Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf
IL281082A (en) Compositions of cxcr4 inhibitors and methods of preparation and use
DK3963021T3 (da) Stabiliserede fluorolefinsammensætninger og fremgangsmåder til anvendelse deraf
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3565520T3 (da) Vandfrie sammensætninger af mtor-hæmmere og fremgangsmåder til anvendelse
DK3870579T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3897833T3 (da) Hæmmere af APOL1 og fremgangsmåder til anvendelse heraf
IL287768A (en) Kcnt1 inhibitors and methods of use
IL287751A (en) Kcnt1 inhibitors and methods of use
DK4267105T3 (da) Antistofsammensætninger og fremgangsmåder til anvendelse deraf
IL286481A (en) Pyridazinones and methods of use thereof
DK4084778T3 (da) Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
DK3852533T3 (da) Pyridazinoner og fremgangsmåder til anvendelse deraf
DK3629838T3 (da) Bærbar stol og fremgangsmåder til fremstilling af en bærbar stol
DK3752251T3 (da) Arginasehæmmere og fremgangsmåder til anvendelse deraf
DK3620174T3 (da) Enhedsdosis af dengue-vaccine og indgivelse deraf
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
IL286620A (en) T cell receptors and methods of use thereof
JP2018172409A5 (ja) 15−hepeを含む組成物および同組成物を使用する方法
DK4355749T3 (da) Tricykliske parp1-hæmmere og deres anvendelse
IL286032A (en) T cell receptors and methods of use thereof
IL286041A (en) T cell receptors and methods of use thereof
DK3630772T3 (da) Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere